about
Molecular characteristics of pediatric high-grade gliomasNew insights and challenges in mismatch repair: getting over the chromatin hurdleDiffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic TargetsQuantitative proteomic analysis of histone modificationsInfluence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer.Distinct chromatin signature of histone H3 variant H3.3 in human cells.HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterationsUnique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.Real-Time Tracking of Parental Histones Reveals Their Contribution to Chromatin Integrity Following DNA Damage.Blurring the line between the DNA damage response and transcription: the importance of chromatin dynamics.Chromatin plasticity in response to DNA damage: The shape of things to come.Reshaping chromatin after DNA damage: the choreography of histone proteins.Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in CancerInvestigation of the human H3.3B (H3F3B) gene expression as a novel marker in patients with colorectal cancerExamining the impact of gene variants on histone lysine methylationEpigenetic mechanisms of tumorigenicity manifesting in stem cells.Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.The genetic signatures of pediatric high-grade glioma: no longer a one-act play.Molecular insights into pediatric brain tumors have the potential to transform therapy.Review of low-grade gliomas in children--evolving molecular era and therapeutic insights.Point mutations in an epigenetic factor lead to multiple types of bone tumors: role of H3.3 histone variant in bone development and disease.Low Grade Gliomas in Children.Driver mutations of cancer epigenomes.PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.Histone Variant H3.3: A versatile H3 variant in health and in disease.Marked for death: targeting epigenetic changes in cancer.The Histone Variant H3.3 in Transcriptional Regulation and Human Disease.The histone variant H3.3 claims its place in the crowded scene of epigenetics.Replication-Independent Histone Variant H3.3 Controls Animal Lifespan through the Regulation of Pro-longevity Transcriptional Programs.Epigenetics meets metabolism through PHB-mediated histone H3.3 deposition by HIRA.Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.Functional IRGM polymorphism is associated with language impairment in glioma and upregulates cytokine expressions.Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.Molecular Basis of Pediatric Brain Tumors.H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
P2860
Q26860786-8716BAFC-04C7-419E-902C-2E1E0ECBB595Q27011117-E2E6C92E-1DFE-4872-9530-591D824DCF37Q30251385-EA0D4375-06F3-4F0F-96A0-70C7893E8A8DQ30375585-671DCA13-07C1-4EDF-AB7E-6DDA04841AB3Q33675577-7A3D0E3A-AA54-4F7B-ACF7-4E4D6F307EACQ34183341-98236689-3647-4186-9008-337FDD56BF03Q34697738-C4C8B03D-FE7F-49F5-B1FD-4F3289CB395BQ35206259-4D4FF838-9A1F-4E93-BEA9-84ED89F0204CQ36515529-D2156D41-1A06-4284-BC3D-E4CA619266BFQ36561184-8006CF22-2B33-4B4C-944A-5F7397D0A4FAQ37341755-9D761CC2-178A-40D2-9074-D04B791D42D1Q37418002-18E2209F-D0A2-4006-89E1-82E0B5B917EFQ37418006-3AE04FE1-2201-4C87-9B01-BAF73C58AEC8Q37418010-E87EA7C2-EAAC-4FB4-BCCB-948736A5E103Q37629542-9D57D457-A815-4944-A7DD-E84E5781DA22Q37677529-8B9CF184-3544-41C1-8B30-DA67F7FA82F9Q38214535-C3C97EED-9F7B-4E35-828D-C205A794C15EQ38220397-44154909-8010-42A5-A560-6963EBCBD10DQ38223007-56521150-6647-46E1-954C-9DE6C0C7DD7DQ38248990-B30FE6B7-6079-4ABD-AFD7-FC7E13BD6297Q38268366-68764D29-1051-448E-8478-4C6CEA3DE6BCQ38365733-1B10B251-8273-4340-9738-503FBA8E43F7Q38544292-2FA2F094-4882-4A4A-9027-6097927C8054Q38569310-0273ADB4-7302-4150-89FE-0A2F7E3CE8DAQ38639828-B0AD9490-C8E3-4CDF-8AE4-241BCB902435Q38655716-0CBCA7E6-FF0B-4B04-8BA8-DE2DB81FF33EQ38716435-0415C78F-6CFF-404D-96BA-0E78A18E7E1CQ38747872-5746C57B-596C-4CFC-9E21-C76D107ECD5CQ39022741-ADB2FFDD-F63B-4C48-9AE3-D2203A486203Q39173837-50A5F835-EFB4-4EAA-BB3F-B29ECC9F4BD1Q41586925-DF5FEF30-D1BF-48F8-BFC7-0CAF6AA0E5ABQ42342118-287C758F-D361-4183-8113-BB6934AC349BQ43213926-69E29037-2E53-4BBA-821E-1BF55B4DD512Q43595553-3386802C-D60A-4F51-A259-70EA791C32BDQ45784223-3F4B0EE2-A9C5-4E40-914C-4A349D6E3FC0Q47436402-B0D38BC2-3E3C-4084-A260-E19D9B5603D5Q47592896-BEA1EC80-4C71-4190-80B6-81A033753B13Q48023007-A8A27C9C-10E6-4D8F-A5AA-8D2676F46934Q48224642-F548F2A7-D5FF-48CA-B45D-A8C300EE9FC4Q50324483-C11304B8-2AF1-4426-B049-02563442EA23
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Histone H3.3 mutations: a variant path to cancer.
@en
type
label
Histone H3.3 mutations: a variant path to cancer.
@en
prefLabel
Histone H3.3 mutations: a variant path to cancer.
@en
P2860
P1433
P1476
Histone H3.3 mutations: a variant path to cancer.
@en
P2093
Benjamin T K Yuen
P2860
P304
P356
10.1016/J.CCR.2013.09.015
P577
2013-11-01T00:00:00Z